Mepolizumab therapy in severe asthma – a study of long term efficacy and safety
C. Reilly (Birmingham (West Midlands), United Kingdom), R. Anandavelu (Birmingham (West Midlands), United Kingdom), J. Marsh (Birmingham (West Midlands), United Kingdom), J. Sullivan (Birmingham (West Midlands), United Kingdom), F. O'Riordran (Birmingham (West Midlands), United Kingdom), S. Cotterill (Birmingham (West Midlands), United Kingdom), L. White (Birmingham (West Midlands), United Kingdom), A. Mansur (Birmingham (West Midlands), United Kingdom)
Source: International Congress 2022 – Asthma biologics in real life studies
Session: Asthma biologics in real life studies
Session type: Thematic Poster
Number: 2403
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Reilly (Birmingham (West Midlands), United Kingdom), R. Anandavelu (Birmingham (West Midlands), United Kingdom), J. Marsh (Birmingham (West Midlands), United Kingdom), J. Sullivan (Birmingham (West Midlands), United Kingdom), F. O'Riordran (Birmingham (West Midlands), United Kingdom), S. Cotterill (Birmingham (West Midlands), United Kingdom), L. White (Birmingham (West Midlands), United Kingdom), A. Mansur (Birmingham (West Midlands), United Kingdom). Mepolizumab therapy in severe asthma – a study of long term efficacy and safety. 2403
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|